(Q36989859)

17 August 2017

1 reference

title

Routine pharmacogenetic testing in clinical practice: dream or reality? (English)

1 reference

17 August 2017

Iris Grossman

1

1 reference

17 August 2017

publication date

1 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1449-1459

1 reference

The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenomics and the drug discovery pipeline: when should it be implemented?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenetic perspectives gained from twin and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

The dosing of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Metabolic drug interactions with newer antipsychotics: a comparative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Investigation of serotonin-related genes in antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

The pharmacogenomics of selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenetics in drug regulation: promise, potential and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenomics: from bedside to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Trick or treat: the effect of placebo on the power of pharmacogenetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Should pharmacogenomic studies be required for new drug approval?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

The distinctive nature of HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Can pharmacogenetics help rescue drugs withdrawn from the market?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

Pharmacogenetics of Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1449

10.2217/14622416.8.10.1449

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference